Experience

• • Represented Xilio Therapeutics in connection with in the equity investment by Gilead Sciences, Inc. for an aggregate purchase price of approximately $13.5 million and private placement equity financing of approximately $11.3 million in 2024.
  • Represented MicroStrategy Incorporated in connection with a Rule 144A offering of Rule 144A offering of $603.75 million in convertible senior notes in 2024. This transaction was the second issuance of senior convertible notes in a ten-day period by MicroStrategy, with a total aggregate principal amount of more than $1.4 billion.
  • Represented Thermo Fisher Scientific Inc. in connection with its inaugural offer and sale $1.070 billion of CHF-denominated bonds, in an offering that was the largest issuance by a foreign issuer of Swiss franc bonds in seven years in 2024.
  • Represented MicroStrategy Incorporated in connection with a Rule 144A offering of $800 million in convertible senior notes in 2024—the only marketed convertible note offering in the past two years which achieved a coupon rate of less than 1% paired with a conversion premium of greater than 40%.
  • Represented TechTarget, Inc. in connection with its $350 million strategic combination with Informa Tech’s digital businesses in 2024.
  • Represented underwriters in connection with the $316.2 million follow-on public offering of Kymera Therapeutics, Inc. in 2024.
  • Represented underwriters in connection with the $34.5 million follow-on public offering of Milestone Pharmaceuticals Inc. in 2024.
  • Represented Thermo Fisher Scientific Inc. in connection with its public offering of $2.95 billion in senior notes in 2023, and with its public offering of $1.2 billion USD and €1.25 billion EUR Notes in November 2022, and in connection with pricing an offering of ¥109.5 billion aggregate principal amount of yen-denominated senior notes in October 2022.
  • Represented Eastman Chemical Company in connection with its inaugural green bond offering of $500 million aggregate principal amount of 5.750% notes in 2023.
  • Represented underwriters and exchange agents in multiple concurrent transactions by Avadel Pharmaceutics plc, including a $143.8 million follow-on equity offering and a $96 million exchange of convertible notes in 2023.
  • Represented underwriters in connection with the $193.6 million initial public offering and $225.0 million follow-on public offering of CinCor Pharma, Inc. in 2022.
  • Represented AVEO Oncology in connection with its sale to LG Chem in an all-cash transaction with an implied equity value of approximately $566 million in 2023.
  • Represented underwriters in connection with the $190.0 million initial public offering and $246.3 million follow-on public offering of Amylyx Pharmaceuticals, Inc. in 2022.
  • Represented Xilio Therapeutics, Inc in connection with its $117.6 million initial public offering in 2021.
  • Represented MicroStrategy Incorporated, in connection with a Rule 144A offering of $1.05 billion of convertible senior notes in 2021—the first convertible note offering in which the stated use of proceeds was to purchase bitcoin.
  • Represented a Nasdaq-listed leading, clinical stage gene editing company in connection with a $265 million underwritten public offering of common stock in 2021.
  • Represented one of the nation’s largest and most diversified television broadcasting companies in connection with a private Rule 144A offering of $3.05 billion of senior secured notes and $1.825 billion of senior unsecured notes in 2019—the largest US high-yield bond offering since 2016.
  • Represented an NYSE-listed mixed-use property real estate investment trusts in connection with an underwritten public offering of $400 million of green bonds in 2019.
  • Represented a Nasdaq-listed independent oil and natural gas company in its sale to an NYSE-listed independent oil and natural gas company for $71 million in 2019.
  • Represented an NYSE-listed triple net lease real estate investment trusts in more than $2 billion of underwritten public offerings of common stock, preferred stock, senior unsecured notes and convertible notes.
  • Represented numerous public companies, placement agents, and sales agents in connection with the establishment of “at-the-market” sales arrangements, PIPE financings and other strategic financings.
  • Represents numerous SEC reporting companies in connection with Exchange Act compliance and corporate governance matters.